title: [Still a place for hormone replacement therapy?].
abstract: Hormone replacement therapy (HRT) remains the most efficient treatment to alleviate climacteric symptoms. The drastic decline in their prescription following the WHI is not fully justified. Benefits might be more important than harm in women 50-60 years. French way of treatment does not increase the risk in thrombosis nor stroke and breast cancer risk is less important than with other regimen. One of the major benefits of HRT is the decrease in type 2 diabetes with all the treatments including the French ones. The results of the American randomized trials cannot be fully extrapolated to young postmenopausal women with less cardiovascular risk factors.
authors.affiliation: Université Paris-Descartes, Port Royal-Cochin, unité de gynécologie médicale, 75014 Paris, France. Electronic address: anne.gompel@cch.aphp.fr.
authors.forename: Anne
authors.initials: A
authors.lastname: Gompel
mesh_terms: D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005602:France; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D014481:United States; D016387:Women's Health